{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:23:39Z","timestamp":1781706219864,"version":"3.54.5"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["943656"],"award-info":[{"award-number":["943656"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cancer is a leading cause of death worldwide. Multidrug resistance (MDR) is a main reason of chemotherapy failure in many patients and is often related to overexpression of ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp\/ABCB1). Agents that are capable of modulation of the activity of these transporters might be effective in overcoming MDR. In this study, a new set of 1,4,5,6,7,8-hexahydro 5-oxo quinoline-3-carboxamide derivatives bearing 4-methylthiazole moiety and their tetrahydroquinoline counterparts were synthesized. MDR reversal activity of these 16 newly synthesized derivatives was tested in P-gp overexpressing MES-SA-DX5 human uterine sarcoma cells by flow cytometric determination of Rhodamine123 efflux. The effect of the most potent compounds in induction of apoptosis and alterations of cell cycle was examined in these cells by a flow cytometric method. Inherent cytotoxicity of the synthesized compounds was evaluated against MCF-7, A-549 and K562 cancer cell lines, as well as MES-SA-DX5 and their parental non-resistant MES-SA and also HEK-293 non-cancerous cells by MTT assay. Compounds A1 and A2 with 5-oxo-hexahydroquinoline structure bearing 2,4-dichlorophenyl and 4-bromophenyl moieties, respectively, and their tetrahydroquinoline counterparts B1 and B2 significantly blocked P-gp efflux, induced apoptosis and showed the highest cytotoxicities against MES-SA-DX5 cells. However, only A2 and B2 compounds were relatively selective against cancer and MDR cells as compared to non-resistant and non-cancerous cells. These findings demonstrate that 5-oxo-hexahydroquinoline and 5-oxo-tetrahydroquinoline derivatives represent promising agents with therapeutic potential in drug resistant cancers.<\/jats:p>","DOI":"10.3390\/molecules25081839","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T13:01:39Z","timestamp":1587042099000},"page":"1839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents"],"prefix":"10.3390","volume":"25","author":[{"given":"Omolbanin","family":"Shahraki","sequence":"first","affiliation":[{"name":"Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan 98167-43463, Iran"},{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Khoshneviszadeh","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"},{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Dehghani","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"},{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mohabbati","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Tavakkoli","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-8706","authenticated-orcid":false,"given":"Luciano","family":"Saso","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology \u201cVittorio Erspamer\u201d, Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmeh","family":"Edraki","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-5198","authenticated-orcid":false,"given":"Omidreza","family":"Firuzi","sequence":"additional","affiliation":[{"name":"Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz 71348-53734, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP\u2013dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152013804487380","article-title":"New insight into p-glycoprotein as a drug target","volume":"13","author":"Breier","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/138945006777709520","article-title":"The functions and structure of ABC transporters: Implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR)","volume":"7","author":"Teodori","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/092986708783503258","article-title":"Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance","volume":"15","author":"Li","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bcp.2007.12.001","article-title":"Inhibition of P-glycoprotein (ABCB1)-and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1\u00ae","volume":"75","author":"Robey","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1747-0285.2007.00565.x","article-title":"Synthesis, QSAR and calcium channel modulator activity of new hexahydroquinoline derivatives containing nitroimidazole","volume":"70","author":"Miri","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1016\/j.bmc.2006.03.016","article-title":"Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1, 4-dihydropyridines as calcium channel antagonist","volume":"14","author":"Miri","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.drudis.2009.08.004","article-title":"Dihydropyridines: Evaluation of their current and future pharmacological applications","volume":"14","author":"Edraki","year":"2009","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1080\/10641960802580232","article-title":"Nimodipine and its use in cerebrovascular disease: Evidence from recent preclinical and controlled clinical studies","volume":"30","author":"Tomassoni","year":"2008","journal-title":"Clin. Exp. Hypertens"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1389557513666131119204126","article-title":"1,4-Dihydropyridines: A class of pharmacologically important molecules","volume":"14","author":"Khedkar","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2174\/1871520616666161206143251","article-title":"Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-Cancer Agent","volume":"17","author":"Viradiya","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.bmc.2017.04.008","article-title":"Dimeric isoxazolyl-1, 4-dihydropyridines have enhanced binding at the multi-drug resistance transporter","volume":"25","author":"Steiger","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1016\/j.bmc.2014.09.023","article-title":"Thieno [2, 3-b] pyridines\u2014a new class of multidrug resistance (MDR) modulators","volume":"22","author":"Krauze","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2014.10.058","article-title":"Cytotoxic and multidrug resistance reversal activities of novel 1, 4-dihydropyridines against human cancer cells","volume":"746","author":"Shekari","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejmech.2014.01.011","article-title":"Synthesis and 3D-QSAR study of 1, 4-dihydropyridine derivatives as MDR cancer reverters","volume":"74","author":"Radadiya","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1039\/C7MD00178A","article-title":"Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: Design, synthesis, biological evaluation and molecular docking analysis","volume":"8","author":"Ranjbar","year":"2017","journal-title":"MedChemComm"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s12272-013-0149-8","article-title":"Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines","volume":"36","author":"Firuzi","year":"2013","journal-title":"Arch. Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/DDDT.S119995","article-title":"Novel 5-oxo-hexahydroquinoline derivatives: Design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study","volume":"11","author":"Shahraki","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.taap.2018.10.025","article-title":"5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells","volume":"362","author":"Ranjbar","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/1735-5362.251855","article-title":"Searching for new cytotoxic agents based on chromen-4-one and chromane-2,4-dione scaffolds","volume":"14","author":"Gaspar","year":"2019","journal-title":"Res. Pharm. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/8\/1839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:31:22Z","timestamp":1760362282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/8\/1839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["molecules25081839"],"URL":"https:\/\/doi.org\/10.3390\/molecules25081839","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}